Home > Market > Market Stats > Cipla
  1. S&P BSE SENSEX
    54,884.66 632.13 (1.17%)
  1. NIFTY 50 D
    Delayed by 15 mins

    16,352.45 182.3 (1.13%)
  1. NIFTY BANK D
    Delayed by 15 mins

    35,613.3 518.4 (1.48%)
  1. S&P BSE MIDCAP
    22,517.74 374.29 (1.69%)

CIPL.BO Cipla - Share price

966.15 1.75 (0.18%) 27 MAY 2022 09:59:54
966.35 1.8 (0.19%) 27 May 2022 10:25:19
Add Stock to Portfolio / Watchlist on mint Genie + Add Stock
  1. Open price970.7
  2. Prev close964.4
  3. Day high978.4
  4. Day low960.1
  5. 52 week high1083.15
  6. 52 week low850.0
  7. Bid quantity0.0
  8. Volume36636
  1. Open price970.1
  2. Prev close964.55
  3. Day high977.8
  4. Day low960
  5. 52 week high1083
  6. 52 week low850
  7. Bid quantity
  8. Volume1249374

Cipla Financials

Standalone
Revenue
19,159.59
Total Revenue
19,159.59
Costof Revenue Total
8,328.64
Gross Profit
10,830.95
Selling/ General/ Admin Expenses Total
6,031.69
Research Development
1,327.3
Depreciation/ Amortization
1,000.57
Interest Exp( Inc) Net- Operating Total
25.5
Unusual Expense( Income)
64.54
Other Operating Expenses Total
399.33
Total Operating Expense
15,960.05
Operating Income
3,199.54
Interest Inc( Exp) Net- Non- Op Total
212.1
Gain( Loss)on Saleof Assets
30.1
Other Net
66.3
Net Income Before Taxes
3,290.06
Provisionfor Income Taxes
888.76
Net Income After Taxes
2,401.3
Minority Interest
16.36
Equity In Affiliates
-127.9
Net Income Before Extra Items
2,404.87
Net Income
2,404.87
Income Availableto Com Excl Extra Ord
2,404.87
Income Availableto Com Incl Extra Ord
2,404.87
Diluted Net Income
2,404.87
Diluted Weighted Average Shares
80.73
Diluted EPS Excluding Extra Ord Items
29.79
DPS- Common Stock Primary Issue
5
Diluted Normalized EPS
30.35
COMPANY INFORMATION
Cipla Limited is an India-based company that is primarily engaged in the business of pharmaceuticals. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 46 manufacturing sites.
Industry Biotechnology & Drugs
ISIN INE059A01026
BSE code 500087
NSE code CIPLA
Global Chief Executive Officer, Managing Director, Executive DirectorUmang   Vohra
Executive Vice Chairman of the BoardSamina   Hamied
Interim Chief Financial OfficerDinesh   Jain
CEO Cipla South Africa and Regional Head Africa and AccessPaul   Miller
Global Chief Technology OfficerGeena   Malhotra
Global Chief Scientific OfficerPradeep   Bhadauria
Compliance Officer, Company SecretaryRajendra   Chopra
Global Head Supply ChainSwapn   Malpani
Global Chief People OfficerRaju   Mistry
Global Head of Quality - Medical Affairs and PharmacovigilanceRanjana   Pathak
NEWS - Cipla
View More News
Recommended For You
×
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsFeedbackRedeem a Gift CardLogout